Ascelia Pharma publishes Orviglance liver MRI contrast agent study in JMRI

Bitget2026/09/24 05:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ascelia Pharma announced publication of a peer-reviewed Orviglance clinical study in the Journal of Magnetic Resonance Imaging.
Results were already presented via the journal article, not flagged for a future medical meeting.
Study assessed a single oral dose in adults with hepatic impairment versus those without impairment.
Publication supports Orviglance’s differentiated profile as a manganese-based liver MRI contrast agent, reinforcing its clinical development rationale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascelia Pharma AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ascelia Pharma publishes Orviglance liver MRI contrast agent study in JMRI

You may also like

Crypto prices